慢性血栓栓塞性肺高血压中的抗凝药:更新的系统性审查和元分析
Filippo Catalani1, Emanuele Valeriani2,3, Walter Ageno4
1Department of Internal Medicine, Regional Hospital of Bellinzona e Valli, Ente Ospedaliero Cantonale (EOC), Bellinzona, Switzerland.
Internal and emergency medicine
|January 20, 2026
概括
直接口服抗凝剂 (DOAC) 与维生素K对抗剂 (VKA) 在治疗慢性血栓栓塞性肺高血压 (CTEPH) 中同样有效和安全. 这一系统性审查表明,对于没有禁忌的CTEPH患者,可以考虑DOAC.
科学领域:
- 心脏病学 心脏病学
- 肺部医学 肺部医学
- 药理学 药理学是指药理学的学科.
背景情况:
- 慢性血栓栓塞性肺高血压 (CTEPH) 是肺栓塞 (PE) 的严重并发症.
- 对CTEPH患者来说,终身抗凝药治疗对于预防PE复发至关重要.
- 维生素K对抗剂 (VKA) 是传统的护理标准,但直接口服抗凝剂 (DOAC) 越来越多地使用.
研究的目的:
- 在CTEPH患者中比较DOAC与VKA的疗效和安全性.
- 评估关键的临床结果,包括静脉血栓栓塞 (VTE) 复发,出血事件和死亡率.
主要方法:
- 随机和观察性研究的系统审查和元分析.
- 包括12项研究,包括4071名被诊断患有CTEPH的患者.
- 分析了诸如VTE复发,严重出血和全因死亡率等结果.
主要成果:
- 在VTE复发方面,DOAC和VKA之间没有发现显著差异 (RR 0.99).
- 两组抗凝剂之间的出血事件 (RR 0.77) 和全因死亡率 (RR 0.58) 没有显著差异.
- 风险试验和前性研究的敏感性分析证实了这些发现.
结论:
- 直接口服抗凝剂 (DOACs) 在CTEPH管理中表现出与维生素K抗剂 (VKAs) 相当的疗效和安全性.
- 对于CTEPH患者来说,DOAC可能是一个可行的替代品,前提是没有临床禁忌.
- 建议进行进一步的大规模随机对照试验,以巩固这些结论.
更多相关视频
相关概念视频
Pulmonary Hypertension: Classification and Pathogenesis
591
Pulmonary hypertension (PH) is a severe health condition in which the mean pulmonary arterial pressure increases to 25 mmHg or more, even when the body is at rest. This high pressure in the blood vessels that transport blood from the heart to the lungs can cause various symptoms, including shortness of breath, can lead to right heart failure, and significantly affect the overall quality of life.
There are various classifications for PH, each relating to different underlying causes and also...
There are various classifications for PH, each relating to different underlying causes and also...
591
Chronic Obstructive Pulmonary Disease
2.3K
COPD is defined as a heterogeneous lung condition marked by persistent respiratory symptoms such as dyspnea, cough, and sputum production, caused by abnormalities in the airways that cause airflow obstruction.
Smoking is a primary risk factor for COPD, with over 80% of patients having a history of it. Patients typically experience progressive dyspnea or labored breathing, frequent coughing, and recurrent pulmonary infections. Many eventually succumb to respiratory failure, characterized by...
Smoking is a primary risk factor for COPD, with over 80% of patients having a history of it. Patients typically experience progressive dyspnea or labored breathing, frequent coughing, and recurrent pulmonary infections. Many eventually succumb to respiratory failure, characterized by...
2.3K
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
2.2K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
2.2K
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
577
Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
577
Chronic Obstructive Pulmonary Disease-I: Introduction
3.6K
Chronic Obstructive Pulmonary Disease (COPD) is a long-lasting respiratory condition requiring continuous attention and care. It is a progressive lung disease that leads to breathing challenges due to airflow obstruction. It manifests as persistent respiratory symptoms and restricted airflow resulting from abnormalities in the airways and alveoli, usually due to long-term exposure to harmful particles or gases. COPD mainly consists of two primary conditions: emphysema and chronic bronchitis.
3.6K
Chronic Obstructive Pulmonary Disease-V: Management
3.1K
Managing Chronic Obstructive Pulmonary Disease (COPD) involves a multifaceted approach to reduce symptoms, prevent exacerbations, improve overall health status, and slow disease progression. Key strategies include lifestyle modifications, pharmacotherapy, supportive therapies, and, in some cases, surgery. Here is an overview of the primary COPD management strategies:
Smoking Cessation
Smoking Cessation
3.1K


